PD-1/PD-L1
Gli inibitori di PD-1/PD-L1 sono inibitori del checkpoint immunitario che bloccano l'interazione tra la proteina di morte cellulare programmata 1 (PD-1) sui linfociti T e il suo ligando PD-L1 sulle cellule tumorali. Questa interazione sopprime normalmente la risposta immunitaria e permette alle cellule tumorali di sfuggire al riconoscimento immunitario. Inibendo PD-1/PD-L1, questi inibitori potenziano la capacità del sistema immunitario di riconoscere e distruggere le cellule tumorali, inducendo apoptosi e regressione tumorale. Gli inibitori di PD-1/PD-L1 sono fondamentali nella ricerca sull'immunoterapia e nel trattamento del cancro. Presso CymitQuimica, offriamo una gamma di inibitori di PD-1/PD-L1 di alta qualità per supportare la tua ricerca in immuno-oncologia, apoptosi e terapia del cancro.
Trovati 126 prodotti di "PD-1/PD-L1"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tuvonralimab
CAS:Tuvonralimab, a combo of anti-PD-1/IgG4 and anti-CTLA-4/IgG1 antibodies, blocks dual immune checkpoints.Purezza:95% - 95%Colore e forma:LiquidReozalimab
CAS:Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, antitumour and enhances T-cell activation in vitro.Purezza:95% - 98.1% (SDS-PAGE); 96.2% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:144.16 kDaLesabelimab
CAS:Lesabelimab (LDP) is an anti-CD274 monoclonal antibody of the immunoglobulin G1-kappa subclass.Colore e forma:LiquidAnti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is an IgG2a, κ antibody inhibitor derived from mice, targeting phosphorylated PD-1/CD279 in both mice and humans.Colore e forma:Odour LiquidAnti-Mouse PD-1 Antibody (S-5001)
Anti-MousePD-1Antibody (S-5001) is an IgG1 antibody inhibitor that targets mouse PD-1.Colore e forma:Odour LiquidVisugromab
CAS:Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15.Purezza:95% - 98.8% (SDS-PAGE); 97.5% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:144.50 kDaIvonescimab
CAS:Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, NSCLC).Purezza:95% - >95.0% (SDS-PAGE); 98.99% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:201.12 kDaPD-1/PD-L1-IN-NP19
CAS:PD-1/PD-L1-IN-NP19: a PD-1/PD-L1 inhibitor with 12.5 nM IC50, may boost antitumor immunity.Formula:C33H31ClN2O4Purezza:96.70%Colore e forma:SolidPeso molecolare:555.06PD-1/PD-L1-IN-20
CAS:PD-1/PD-L1-IN-20 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interaction.Formula:C30H26BrClN2O3Colore e forma:SolidPeso molecolare:577.9PD-1-IN-22
CAS:PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor(IC50 of 92.3 nM).Formula:C25H25N5O4Purezza:99.51%Colore e forma:SolidPeso molecolare:459.5Ref: TM-T12379
1mg109,00€2mg163,00€5mg243,00€10mg355,00€25mg532,00€50mg750,00€100mg1.009,00€500mg2.035,00€1mL*10mM (DMSO)284,00€PD-1/PD-L1-IN-27
CAS:PD-1/PD-L1-IN-27: potent anti-cancer, IC50 134nM, minimal T cell harm, boosts CD8+ T cells, reduces fatigue.Formula:C44H35NO6Purezza:98%Colore e forma:SolidPeso molecolare:673.75ASC-69
CAS:ASC-69 (APY69) is a promising potent inhibitor of the PD-1/PD-L1 signaling pathway, classified as a small-molecule compound [1].Formula:C19H19N7Purezza:98%Colore e forma:SolidPeso molecolare:345.4PD-1/PD-L1-IN-26
CAS:PD-1/PD-L1-IN-26 is a strong inhibitor with IC50 of 0.0380 μM that may boost immune response in cancer by aiding CD4+ T cell entry to tumors.Formula:C43H52N4O8Purezza:98%Colore e forma:SolidPeso molecolare:752.89PD-1/PD-L1-IN-33
CAS:PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM.Formula:C26H27N5OPurezza:98%Colore e forma:SolidPeso molecolare:425.53PD-L1-IN-2
CAS:PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity.Formula:C33H38N4O6Purezza:98%Colore e forma:SolidPeso molecolare:586.68PD-1/PD-L1-IN-34
CAS:PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1/PD-L1 interaction (IC 50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1Formula:C35H33ClN2O3Purezza:98%Colore e forma:SolidPeso molecolare:565.1PD-L1-IN-3
CAS:PD-L1-IN-3 is a PD-1/PD-L1 inhibitor for the study of tumors and immune diseases.Formula:C19H15ClFN2OSPurezza:99.47%Colore e forma:SoildPeso molecolare:373.85PD-L1-IN-7
CAS:PD-L1-IN-7 (compound CB31) serves as a PD-L1 inhibitor, effectuating PD-L1 internalization and retention within cells. It restrains the PD-1/PD-L1 interaction (IC 50: 0.2 nM), alters glycosylation patterns, and facilitates PD-L1 degradation. Additionally, PD-L1-IN-7 enhances T cell infiltration, boosts T cell function, and augments the capacity to destroy tumor cells.Formula:C46H50N6O7Colore e forma:SolidPeso molecolare:798.93PD-1-IN-17
CAS:PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.Formula:C13H22N6O7Purezza:99.6%Colore e forma:SolidPeso molecolare:374.35PD-L1/VISTA-IN-1
CAS:PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual inhibitor targeting PD-L1 and VISTA. It effectively hinders the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), leading to the reactivation of T cells. Additionally, PD-L1/VISTA-IN-1 exhibits antitumor activity.Formula:C22H24N4O4Colore e forma:SolidPeso molecolare:408.45Enpp-1-IN-25
CAS:Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.Formula:C15H21N5O4SColore e forma:SolidPeso molecolare:367.423PD-1/PD-L1-IN-55
CAS:PD-1/PD-L1-IN-55 (compound D6) is a potent PD-1/PD-L1 inhibitor with an IC50 of 4.8 nM. It enhances IFN-γ secretion and decreases the proportion of late apoptosis due to PD-L1.Formula:C25H23ClN2O3Colore e forma:SolidPeso molecolare:434.92LLW-018
CAS:LLW-018 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 2.61 nM. It can disrupt the PD-1/PD-L1 interaction, with a cell-based PD-1/PD-L1 blocking bioassay IC50 value of 0.88 μM. LLW-018 holds potential for research in immune-related diseases.Formula:C35H38Cl2N4O5SPeso molecolare:697.67PD-1/PD-L1-IN-53
CAS:PD-1/PD-L1-IN-53 (compound B3) serves as an inhibitor targeting both the PD-1/PD-L1 and VISTA signaling pathways. It is utilized in cancer research.Formula:C31H37N3O4Colore e forma:SolidPeso molecolare:515.64INCB086550
CAS:INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.Formula:C41H39N7O4Purezza:98.49%Colore e forma:SolidPeso molecolare:693.79PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.
Colore e forma:Odour Liquid
